Rentosertib Shows Potential to Lower Biological Age in Small AI Drug Study

The study also identified changes in proteins and biological pathways associated with cellular senescence and metabolism, alongside changes linked to fibrosis. However, the researchers cautioned that the proteomic clocks could not distinguish whether the changes reflected an effect on aging itself or improvements related to the underlying lung disease.

That distinction is important because biological age in the study was a calculated measure derived from protein patterns, rather than evidence that patients' chronological age had been reversed or that they would live longer.

The findings also build on Insilico's broader work applying AI to aging research, including efforts to develop AI models that can analyze biological and clinical data for longevity applications. That work has increasingly connected AI drug discovery with aging research.

Clinical Testing Still Focused on Lung Disease

Rentosertib remains an investigational drug rather than an approved anti-aging treatment. Its Phase 2a trial enrolled 71 people with IPF, who received different doses of rentosertib or placebo for 12 weeks. The trial found that the 60 mg once-daily group had a mean improvement in forced vital capacity of 98.4 milliliters, compared with a 20.3-milliliter decline in the placebo group.

The Phase 2a study also reported adverse events across treatment groups, with some patients discontinuing treatment because of liver-related adverse events or diarrhea. The researchers concluded that larger and longer clinical trials were needed.

The new aging analysis does not change that clinical-development path. Instead, it suggests that standard disease trials could potentially incorporate biological-aging measurements alongside conventional measures of disease progression.

The approach reflects a broader principle in AI drug development: computational systems can identify targets, molecules and biological signals, but clinical testing remains necessary to determine whether those signals translate into meaningful health outcomes. AI can reduce blind experimentation in drug discovery, but it does not eliminate the need for experiments.

For now, the rentosertib findings provide evidence of a change in biological-age markers in people with IPF, rather than proof that the drug can slow or reverse aging in healthy people. Further clinical research will be needed to determine whether the signal represents a genuine effect on aging beyond its effects on pulmonary fibrosis.